amylin
pharmaceuticals
said
acquired
worldwide
rights
series
orally
active
compounds
evaluated
ability
reduce
risk
factors
heart
disease.it
said
preclinical
models
compounds
shown
inhibit
formation
plaque
blood
vessels
lowering
cholesterol
acting
anti
oxidants
reducing
inflammation.under
terms
agreement
amylin
responsible
preclinical
evaluation
clinical
development
compounds
hoechst
completion
phase
ii
trials
time
right
enter
collaboration
continue
developing
comound
50-50
cost
profit
sharing
arrangement
